New Gliobastoma Cell Lines: Analysis of Genetic Changes, and Assessment of Sensitivity to Radiotherapy and Immunotherapy

Abstract

The characteristics of six new glioblastoma cell lines obtained from tumor material from patients are presented. The studied glioblastomas do not have mutations in the genes IDH1 and IDH2, which indicated a poor prognosis for their therapy. Two glioblastomas carry the pathogenic mutation p.Arg110Pro in the gene TP53. All cell lines studied express RNA of tumor suppressor and oncogenic isoforms of the p73 protein. The glioblastomas responded differently to radiotherapy, with five of them being more resistant to γ irradiation than the standard A172 glioma line. All six cell lines express RNA genes for vascular endothelial growth factor and its receptor (VEGFR-1) in different ratios. Testing of an immunotherapeutic regimen with monoclonal antibodies to VEGFR-1 on one of the cell lines confirms that the studied glioblastomas are sensitive to blocking vascular growth factor and its receptor. Thus, these glioblastomas can become a promising model for studying the formation of tumor-cell resistance to radiotherapy and the effectiveness of immunotherapy that blocks growth factors and their receptors.